Article Abstract

Treatment of advanced Gall bladder cancer in the real world—can continuation chemotherapy improve outcomes?

Authors: Vikas Ostwal, Rakesh Pinninti, Anant Ramaswamy, Nitin Shetty, Mahesh Goel, Shraddha Patkar, Jimmy Mirani, Chaitali Nashikkar, Shripad Banavali

Abstract

Background: Gemcitabine-Platinum doublet chemotherapy is the standard of care in patients with locally advanced inoperable and metastatic (LA/M) Gall bladder cancers (GBC).
Methods: Consecutive patients with LA/M GBC treated with Gemcitabine-Cisplatin (GC) or Gemcitabine-Oxaliplatin (GO) as first line palliative chemotherapy from January 2013 to June 2015 were retrospectively analysed. Patients who were able to continue chemotherapy beyond 6–8 cycles were separately compared to those who were potential candidates for this approach, but chose not to continue chemotherapy.
Results: A total of 396 patients received first line palliative chemotherapy during the period of analysis, 276 patients (69.6%) were unable to complete 6–8 cycles of chemotherapy, while 120 patients (30.4%) were potential candidates for continuing chemotherapy. Seventy patients (n=120; 58.3%) received a median of 4 cycles of continuation chemotherapy. Median overall survival (OS) for the entire cohort was 7.65 months [95% con dence interval (CI), −7.14 to 8.16], while median event free survival (EFS) was 4.53 months (95% CI, −4.23 to 4.83). Patients receiving continuation chemotherapy had a statistically improved median OS compared to all other patient cohorts, 14.88 months (95% CI, −12.48 to 17.27; P=0.005 on multivariate analysis). Burden/number of sites of metastases, receiving of continuation chemotherapy, t and able to receive second line chemotherapy (CT2) were identi ed on multivariate analysis as prognostic factors for OS.
Conclusions: OS in our study appeared lower than published literature, but a group of patients were identified whose survival could be prolonged by continuing chemotherapy. Easily available factors can predict prognosis of GBC undergoing first line palliative chemotherapy.